July 2nd 2026

By Ailsa Colquhoun

Five products added to DND list

Five products will be granted Discount Not Deducted (DND) status from July 1.

DND status is determined to ensure fair reimbursement for pharmacy owners. However, it does not apply to dispensing doctors.

The designated products are:

• Allopurinol 300mg/5ml oral suspension sugar free
• Budesonide 4mg suppositories
• Iqirvo 80mg tablets
• Liothyronine 25microgram tablets
• Ospolot 20mg/ml oral suspension

Since 2019, some 815 products have been granted DND status, including group items and eligible individual items. The total of DND items now tops 1,300.

Group items cover the following:  

• Cold Chain Storage (ALL)
• Schedule 1, 2 or 3 Controlled Drugs: Products containing drugs listed in Schedules 1, 2 and 3 of the Misuse of Drugs Regulation 2001
• Cytotoxic or Cytostatic item (ALL):
• Immunoglobulins (ALL)
• Insulins for injection (ALL)
• Vaccines and antisera (ALL)
• Unlicensed medicines: ‘Specials’ not listed in Part VIIIB where the product has been sourced from a supplier holding a MHRA specials or importers licence (prescriptions must be endorsed with invoice price less discount/rebate)
• Hazardous chemicals

Individual items must fulfil all three of the following criteria to qualify for entry to the DND list.

• the manufacturer(s), AAH and Alliance do not offer pharmacy owners a discount
• fewer than 500,000 items per year are dispensed of the product
• average net ingredient cost (NIC) per item is more than £50

Community Pharmacy England maintains a list of items with discount not deducted (DND) status.

The DDA is lobbying to address the disparities associated with DND in its new briefing paper: Addressing the Disparities